DMC demonstrates full commercial scale production of L-alanine at record speed
US biobased chemical developer DMC Biotechnologies Inc (DMC) has announced that it has successfully demonstrated full commercial scale for its first product, the amino acid L-alanine. The scale-up process to reach 85m3 fermentation was conducted at EW Biotech GmbH’s facility in Leuna, Germany.
According to a statement, the scale-up results identically tracked the performance at bench and pilot scales, further validating the predictability and scalability of DMC’s Dynamic Metabolic Control technology. Importantly, commercial performance metrics were demonstrated, meaning that no further strain improvements are required to achieve the target selling price.
L-alanine is a small non-essential amino acid in humans and is one of the most widely used for protein construction. This demonstration of process robustness and predictability across the scale of production – from high-throughput screening to full commercial scale has never been demonstrated in the field and represents a major advancement for the company.
This core technology enablement will also be beneficial for DMC’s pipeline of products that will be scaled and commercialized next.
A successful biotech business is about more than exciting science. Demonstration of performance at commercial scale with L-alanine validates the key technology features of robustness and predictability that will be inherent in all of our processes and demonstrates that we are on target with the economics for our lead product. We have reached commercial scale with unprecedented speed and capital efficiency when compared to any other company in the sector, said Dr Matt Lipscomb, CEO, and Co-Founder of DMC.
The scale-up process was conducted at EW Biotech’s facility in Leuna, Germany. EW Biotech is a service provider in the field of process development, scale-up, and custom manufacturing of biotechnological processes.
We are excited to report on the successful technology transfer and scale-up of DMC’s process at the EW Biotech facility. This demonstration of process robustness and predictability of the strain across industrially relevant scales has the potential to radically improve the field of industrial biotechnology, said Michael Katzberg, Managing Director at EW Biotech.